New alliance targets fake drugs: IPR Center partners with Rx-360 to protect patients and supply chains
WASHINGTON — The National Intellectual Property Rights Coordination Center and the International Pharmaceutical Supply Chain Consortium, known as Rx-360, announced a new partnership to strengthen efforts against illicit pharmaceutical trade April 6, protecting a vital sector of the U.S. economy and safeguarding public health. Rx-360 is a nonprofit organization that brings together pharmaceutical and medical device manufacturers to enhance patient safety through stronger global supply chain security, integrity and quality.
“Illicit pharmaceutical trade poses a significant threat to both economic stability and the health of our communities,” said IPR Center Director Ivan Arvelo. “By joining forces with Rx-360, we are expanding our reach and leveraging industry expertise to disrupt these criminal networks and protect patients across the country.”
The partnership combines the IPR Center’s expertise in investigating and disrupting criminal organizations involved in counterfeit pharmaceuticals and medical devices with Rx-360’s global network of pharmaceutical and medical device manufacturers. Together, they will enhance supply chain security, promote best practices and prevent unauthorized products from infiltrating legitimate markets.
“Our partnership with the IPR Center strengthens our shared commitment to protecting patient safety,” said Interim CEO and Senior Director of Supply Chain Security and Brand Protection Ryan Kelly. “By combining the IPR Center’s enforcement capabilities with Rx360’s industry expertise, we are able to better safeguard global pharmaceutical supply chains, prevent counterfeit threats and ensure that patients receive the safe, authentic products they depend on.”
Through this partnership, Rx-360 will facilitate outreach and collaboration between the IPR Center, pharmaceutical manufacturers and government agencies, supporting comprehensive strategies to disrupt illicit trade.
As part of the agreement, the IPR Center will share areas of concern and investigative leads with Rx-360, leveraging its industry relationships to further investigative efforts. Both organizations will conduct outreach and training at industry-led events, fostering stronger relationships within the pharmaceutical community.
This partnership underscores the shared commitment of the IPR Center and Rx-360 to protect public health, ensure fair competition and maintain the integrity of the global pharmaceutical supply chain.